SCHEMBL6480327

SCHEMBL6480327

CC(=O)OC1C/C=C\C[C]Cc2ccccc2C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP7 O15540 2/20 0.35
FABP5 Q01469 2/20 0.35
IDO1 P14902 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB2 P47870 2/20 0.33
FABP3 P05413 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
POLB P06746 1/20 0.33
MTNR1A P48039 2/20 0.32
MTNR1B P49286 2/20 0.32
BCHE P06276 2/20 0.31
GRIN2B Q13224 1/20 0.31
CHRM2 P08172 3/20 0.30
CHRM4 P08173 3/20 0.30
CHRM5 P08912 3/20 0.30
CHRM1 P11229 3/20 0.30
CHRM3 P20309 3/20 0.30
PDE4A P27815 2/20 0.30
PDE4B Q07343 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481758 0.79 FABP7 (0.33) FABP7FABP5IDO1GABRA1GABRB2
SCHEMBL6492257 0.79 IDO1 (0.34) FABP7FABP5IDO1GABRA1GABRB2
SCHEMBL6492097 0.79 TSHR (0.34) FABP7FABP5IDO1GABRA1GABRB2
SCHEMBL6481865 0.78
SCHEMBL6492063 0.77 GABRA1 (0.39) GABRA1GABRB2POLBMTNR1AMTNR1B
SCHEMBL1196934 0.77 FABP7 (0.50) FABP7FABP5IDO1GABRA1GABRB2
SCHEMBL30493000 0.77 FABP7 (0.50) FABP7FABP5IDO1GABRA1GABRB2
SCHEMBL6480324 0.77 FABP7 (0.35) FABP7FABP5IDO1GABRA1GABRB2
SCHEMBL6488003 0.76 GABRA1 (0.39) GABRA1GABRB2POLBMTNR1AMTNR1B
SCHEMBL6480617 0.76 GABRA1 (0.32) GABRA1GABRB2POLBMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288238-A1 Benzocyclodecane derivatives with antitumor activity PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288238-A1 Benzocyclodecane derivatives with antitumor activity H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OR10J3, BCL6 FABP7 3581/4885FABP5 4576/4885IDO1 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.